EGF

Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR) to stimulate cell proliferation, migration, and differentiation in epithelial and mesenchymal cells; it plays a fundamental role in wound healing, skin regeneration, and tissue repair by promoting keratinocyte and fibroblast activation through tyrosine kinase-mediated downstream signaling. EGF activates EGFR tyrosine kinase to initiate PI3K/Akt and MAPK/ERK proliferative signaling cascades; in wound contexts, topically applied recombinant EGF accelerates epithelialization and granulation tissue formation, and injectable EGF has been evaluated for wound bed preparation in diabetic and chronic wounds.

skin regeneration, wound healing, collagen stimulation, post-procedure recovery.

Research on EGF primarily documents effects related to skin regeneration and wound healing and collagen stimulation and post-procedure recovery. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For EGF, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

# Summary Research found that the extraction efficiency of EGF from human amniotic membrane is strongly influenced by multiple interdependent factors, including tissue preservation methods, cryogenic processing, buffer composition (particularly trehalose for stabilization), and protease inhibition strategies. This study demonstrated that systematic optimization of these biological, mechanical, and biochemical parameters can substantially enhance EGF recovery and enable production of standardized, high-potency extracts suitable for clinical applications.